RARE
Ultragenyx Pharmaceutical Stock Analysis
AI Rating
- Quality1/10
- Growth↑ 5/10
- Value↓ 0/10
RARE Growth
- Revenue Y/Y↑ 20.18%
- EPS Y/Y↑ 7.31%
- FCF Y/Y↓ -12.11%
RARE Profitability
- Gross margin ↑ 83.80%
- EPS margin↓ -85.40%
- ROIC 5Y↓ -37.38%
RARE Risk
- Debt / Equity↑ 999.0
- Debt / FCF↓ 1.8
- Interest coverage↑ 999.0
Ultragenyx Pharmaceutical stock is less volatile than the overall market, so it's low risk. We give it a Poor risk rating.